BioReliance Deal Receives Regulatory Green Light
January 26, 2012
Tags:
January 26, 2012
The $350 million sale of BioReliance by Avista Capital Partners to Sigma-Aldrich (NASDAQ: SIAL) has been granted early termination by the FTC. The transaction was announced earlier this month and is expected to close this quarter. BioReliance provides biopharmaceutical testing services and was acquired by Avista in 2007.
PitchBook for
Profile PreviewsUS Headquarters
European Headquarters
Asia-Pacific Headquarters
© 2022 PitchBook. Win what’s next. All rights reserved.